Search

Your search keyword '"D'Ambrosio, Lorenzo"' showing total 415 results

Search Constraints

Start Over You searched for: Author "D'Ambrosio, Lorenzo" Remove constraint Author: "D'Ambrosio, Lorenzo"
415 results on '"D'Ambrosio, Lorenzo"'

Search Results

152. Representation formulae of solutions of second order elliptic inequalities.

153. Managing pazopanib toxicity in the treatment of advanced soft tissue sarcoma

154. Case 1 – Multidisciplinary treatment of a giant cell tumor of the bone affecting the sacrum of a young woman

156. Letter to the Editor

157. Multidisciplinary management of vertebral metastases in patients not amenable to surgery

158. Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.

160. Abstract 2298: Cytokine-induced killer cells redirected with anti-CD44v6 chimeric antigen receptor against soft tissue sarcomas

161. Abstract 3709: PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR)

162. A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.

163. Temozolamide and irinotecan in metastatic Ewing sarcoma: An Italian Sarcoma Group and Royal Marsden Hospital join study.

166. Blow-up profile for solutions of a fourth order nonlinear equation

167. Quasilinear elliptic systems in divergence form associated to general nonlinearities.

168. Fluorine-18 fluorodeoxyglucose (18 FDG)-uptake assessment of PDGFRA mutant gastrointestinal stromal tumors (GIST): A retrospective multicenter Italian study.

169. Uniqueness of ��-regular solutions of quasilinear elliptic problems

171. Foreword

172. Pattern of relapse in limb/girdle low-grade liposarcoma/atypical lipomatous tumor (ALT) during guidelines-suggested follow up (FU).

173. C-reactive protein (CRP) and peripheral blood monocyte count (PBMC) in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (TR): correlation with progression-free survival (PFS).

174. Improved [formula omitted]-Poincaré inequalities on the hyperbolic space.

175. Quasilinear elliptic equations with critical potentials.

176. Alpha-fetoprotein elevation in NUT midline carcinoma: a case report.

179. Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature

180. Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models of bone and soft tissue sarcoma (BSTS).

181. Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas

184. A risk-based individualized follow-up after complete surgery as an effective procedure to reduce the relapse (R) impact in GIST patients (pts).

185. Preoperative Tru-Cut biopsy (POB) for the diagnosis of retroperitoneal soft tissue sarcomas (RPS) and risk of local recurrence (LR) compared to primary surgery of the tumor.

186. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

187. Abstract LB-213: The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS).

190. Preclinical study of trabectedin (TR) and poly(ADP-ribose)polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS).

191. Analysis of Hohn (HC) and porth-a-cath (PAC) central venous catheters (CVC) adverse events (AEs) and related costs in advanced soft tissue sarcomas (STS) treated with trabectedin (TR) 24-hour (24-h) infusion therapy.

192. Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results.

193. Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways

194. Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?

Catalog

Books, media, physical & digital resources